1. Home
  2. TRDA vs PRHIZ Comparison

TRDA vs PRHIZ Comparison

Compare TRDA & PRHIZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TRDA
  • PRHIZ
  • Stock Information
  • Founded
  • TRDA 2016
  • PRHIZ N/A
  • Country
  • TRDA United States
  • PRHIZ United States
  • Employees
  • TRDA N/A
  • PRHIZ N/A
  • Industry
  • TRDA Biotechnology: Pharmaceutical Preparations
  • PRHIZ Property-Casualty Insurers
  • Sector
  • TRDA Health Care
  • PRHIZ Finance
  • Exchange
  • TRDA Nasdaq
  • PRHIZ Nasdaq
  • Market Cap
  • TRDA 222.5M
  • PRHIZ 220.0M
  • IPO Year
  • TRDA 2021
  • PRHIZ N/A
  • Fundamental
  • Price
  • TRDA $5.84
  • PRHIZ $20.50
  • Analyst Decision
  • TRDA Strong Buy
  • PRHIZ
  • Analyst Count
  • TRDA 3
  • PRHIZ 0
  • Target Price
  • TRDA $25.67
  • PRHIZ N/A
  • AVG Volume (30 Days)
  • TRDA 350.3K
  • PRHIZ N/A
  • Earning Date
  • TRDA 11-04-2025
  • PRHIZ N/A
  • Dividend Yield
  • TRDA N/A
  • PRHIZ N/A
  • EPS Growth
  • TRDA N/A
  • PRHIZ N/A
  • EPS
  • TRDA N/A
  • PRHIZ N/A
  • Revenue
  • TRDA $79,476,000.00
  • PRHIZ N/A
  • Revenue This Year
  • TRDA N/A
  • PRHIZ N/A
  • Revenue Next Year
  • TRDA N/A
  • PRHIZ N/A
  • P/E Ratio
  • TRDA N/A
  • PRHIZ N/A
  • Revenue Growth
  • TRDA N/A
  • PRHIZ N/A
  • 52 Week Low
  • TRDA $4.93
  • PRHIZ N/A
  • 52 Week High
  • TRDA $21.79
  • PRHIZ N/A
  • Technical
  • Relative Strength Index (RSI)
  • TRDA 51.80
  • PRHIZ N/A
  • Support Level
  • TRDA $5.82
  • PRHIZ N/A
  • Resistance Level
  • TRDA $6.90
  • PRHIZ N/A
  • Average True Range (ATR)
  • TRDA 0.36
  • PRHIZ 0.00
  • MACD
  • TRDA 0.07
  • PRHIZ 0.00
  • Stochastic Oscillator
  • TRDA 45.88
  • PRHIZ 0.00

About TRDA Entrada Therapeutics Inc.

Entrada Therapeutics Inc is a clinical-stage biopharmaceutical company. It aims to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient intracellular delivery into a variety of organs and tissues, resulting in an improved therapeutic index and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. Its oligonucleotide programs are in development for the potential treatment of people living with Duchenne, which are exon 44, 45, 50, and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.

Share on Social Networks: